2006-003001-49: Anti-inflammatory effects of rosiglitazone in patients with stage 4 and 5 chronic kidney disease |
|
|
| Ongoing | 2 | 200 | Europe | Rosiglitazon, 1360, Avandia, Avandia | Leiden University Medical Center | Chronic kidney disease | | | | |
NCT04114136: Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies |
|
|
| Recruiting | 2 | 72 | US | Nivolumab or Pembrolizumab (dependent upon approved indication), Opdivo (nivolumab) or Keytruda (pembrolizumab), Metformin, Glucophage, Glucophage XR, Fortamet, and Glumetza, Rosiglitazone, Avandia | Dan Zandberg | Melanoma, NSCLC, Hepatocellular Carcinoma, Urothelial Cancer, Gastric Adenocarcinoma, HNSCC, Esophageal Adenocarcinoma, Microsatellite Instability-High Solid Malignant Tumor | 04/32 | 04/32 | | |
